title: Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide.
abstract: OBJECTIVE
  To determine the effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide (LPS) or Pansorbin.
  
  
  METHODS
  Monocytes obtained from 10 healthy volunteer donors were stimulated with LPS or Pansorbin and exposed or not to different concentrations of the fluoroquinolone antibiotic moxifloxacin. At 3, 6 and 24 h, the amounts of interleukin-1alpha (IL-1alpha), IL-1beta, IL-6, IL-10, IL-12 (p70) and tumour necrosis factor-alpha (TNF-alpha) were measured in the supernatants of the monocyte cultures using enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Stimulation of human monocytes with either LPS or Pansorbin resulted in a significant increase in secretion of each of the cytokines examined. Treatment of LPS-stimulated monocytes with moxifloxacin significantly inhibited (P < 0.01) secretion of IL-1alpha by monocytes of each of 10 human donors; the secretion of TNF-alpha was significantly inhibited (P < 0.01) in monocytes from six of 10 donors. In general there was a trend towards inhibition of secretion of IL-6, IL-10 and IL-12 (p70), but the inhibitory effect was not statistically significant. Secretion of cytokines by Pansorbin-stimulated monocytes was not significantly inhibited by moxifloxacin.
  
  
  CONCLUSIONS
  Moxifloxacin has immunomodulatory activity through its capacity to alter the secretion of IL-1alpha and TNF-alpha by human monocytes.
authors.affiliation: Research Institute, Palo Alto Medical Foundation, Palo Alto, CA 94301, USA.
authors.forename: F G
authors.initials: FG
authors.lastname: Araujo
authors.forename: T L
authors.initials: TL
authors.lastname: Slifer
authors.forename: J S
authors.initials: JS
authors.lastname: Remington
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D004926:Escherichia coli; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D000077266:Moxifloxacin; D011804:Quinolines; D013211:Staphylococcus aureus; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D000276:Adjuvants, Immunologic; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D007375:Interleukin-1; D008070:Lipopolysaccharides; D011804:Quinolines; D014409:Tumor Necrosis Factor-alpha; D000077266:Moxifloxacin